Melanoma of Unknown Primary (DBCOND0116190)

Identifiers

Synonyms

Not Available

Associated Data

Indicated Drugs and Targets

Not Available

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT04462406	Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial	Ipilimumab Nivolumab Pembrolizumab	treatment	2	recruiting
NCT05341349	Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-100M for the Treatment of Melanoma Brain Metastases	Ipilimumab Nivolumab Pembrolizumab	treatment	1	recruiting
NCT01274338	Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery	Benzalkonium Interferon alfa Interferon alfa-2b Ipilimumab	treatment	3	active_not_recruiting
NCT02129075	A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma	CDX-301 Cancer/testis antigen 1 Carboxymethylcellulose Hiltonol Lysine Polyinosinic-polycytidylic acid Rasdegafusp alfa	treatment	2	completed
NCT04708418	A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy in Patients With Operable Melanoma	Pembrolizumab Vidutolimod	treatment	2	suspended
NCT03033576	Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma	Ipilimumab Nivolumab	treatment	2	active_not_recruiting
NCT02858869	Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases	Pembrolizumab	treatment	1	completed
NCT04221438	Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement	Binimetinib Encorafenib	treatment	2	active_not_recruiting